BRIEF published on 01/07/2026 at 22:10, 3 months 30 days ago Abivax dévoile ses plans stratégiques pour 2026 Dépôt Réglementaire Perspectives D'Abivax Pour 2026 Marché De La Colite Ulcéreuse Essais Cliniques Sur L'obefazimod Recherche Sur La Maladie De Crohn
PRESS RELEASE published on 01/07/2026 at 22:05, 3 months 30 days ago Abivax présente ses perspectives pour 2026 Abivax présente ses perspectives pour 2026, annonçant des nouveautés dans le traitement de la rectocolite hémorragique, les progrès des essais ABTECT-UC et ENHANCE-CD, et l'avancement de son portefeuille de candidats médicaments Abivax Maladies Inflammatoires Chroniques Rectocolite Hémorragique Essais Cliniques Perspectives 2026
PRESS RELEASE published on 01/07/2026 at 22:05, 3 months 30 days ago Abivax Provides 2026 Corporate Outlook Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
BRIEF published on 12/18/2025 at 22:10, 4 months 19 days ago Abivax rejoint l'indice Nasdaq Biotechnology Biotechnologie Abivax Obefazimod Rectocolite Hémorragique Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 4 months 19 days ago Abivax joins the Nasdaq Biotechnology index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 4 months 19 days ago Abivax Joins Nasdaq Biotechnology Index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology Index
BRIEF published on 12/18/2025 at 22:10, 4 months 19 days ago Abivax intègre l'indice Nasdaq Biotechnology Biotechnologie Abivax Obefazimod Rectocolite Hémorragique Indice Nasdaq Biotechnology
PRESS RELEASE published on 12/18/2025 at 22:05, 4 months 19 days ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology Abivax intègre l'Indice Biotechnologie du Nasdaq, témoignant de sa croissance et de ses avancées cliniques. Le NBI suit les performances des sociétés du secteur Biotechnologie Abivax Nasdaq Clinique NBI
PRESS RELEASE published on 12/18/2025 at 22:05, 4 months 19 days ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology Abivax intègre l'indice Nasdaq Biotechnology, rejoignant le NBI avec impact le 22 décembre 2025. Un pas significatif pour la société de biotechnologie française Biotechnologie Abivax France Nasdaq Biotechnology Indice
PRESS RELEASE published on 12/18/2025 at 22:05, 4 months 19 days ago Abivax to be Added to Nasdaq Biotechnology Index Abivax to be added to Nasdaq Biotechnology Index, reflecting company's progress in developing therapeutics for chronic inflammatory diseases. Inclusion effective December 22, 2025 Biotechnology Abivax Therapeutics Immune Response Nasdaq Biotechnology Index
Published on 05/07/2026 at 11:00, 37 minutes ago Kingfisher Metals Announces Fully Funded 2026 Exploration Program
Published on 05/07/2026 at 09:05, 2 hours 32 minutes ago Nano One Appoints Jason Zandberg as Director of Capital Markets
Published on 05/07/2026 at 05:40, 5 hours 57 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 9 hours 37 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 12 hours 7 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/07/2026 at 11:15, 21 minutes ago LUYUAN Opens European R&D and Innovation Center in Munich, Anchoring Localization with "China R&D + German Engineering"
Published on 05/07/2026 at 11:00, 36 minutes ago Pylontech Recognized as BloombergNEF Tier 1 Energy Storage Manufacturer
Published on 05/07/2026 at 11:00, 37 minutes ago ABB Ltd: ABB share buybacks - April 30, 2026 - May 6, 2026
Published on 05/07/2026 at 10:45, 52 minutes ago REPLOID secures growth financing in the double-digit million-euro range from Raiffeisen Bank International
Published on 05/07/2026 at 10:35, 1 hour 1 minute ago Encouraging New Data: Grafalon Benefits High-Risk Pediatric HSCT Patients in the FORUM Study
Published on 05/07/2026 at 07:43, 3 hours 53 minutes ago ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 17 hours 36 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 17 hours 36 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 17 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
